Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Revance’s neurotoxin development programs.
"Dr. Rubio played key leadership roles in the successful development and approval of several ophthalmic indications for Genentech’s Lucentis* (ranibizumab injection) and has led teams that managed line extensions, created market strategies, and generated disease and product education initiatives,” said Revance President and Chief Executive Officer, Dan Browne. "Dr. Rubio is a published investigator with extensive biologic drug development experience managing early- and late-stage product development, clinical development, medical affairs, and physician relations. We are pleased to add a seasoned drug developer with a proven track record for all phases of product development to our senior management team."
Dr. Rubio comes to Revance from Avalanche Biotechnologies, Inc., where he was Senior Vice President of Translational Medicine. Prior to Avalanche, Dr. Rubio served more than 11 years at Genentech, Inc., ascending through a number of clinical and development management roles to Global Head of Ophthalmology.
Dr. Rubio has an MBA in Health Care Management and Finance from The Wharton School, University of Pennsylvania, and received his Doctor of Medicine from University of California, San Francisco. He completed a Master of Science, Health and Medical Sciences from the University of California, Berkeley, and has a Bachelor of Science, Biological Sciences from the University of Notre Dame.
“The Revance team is focused on advancing its clinical trials in a number of aesthetic and therapeutic indications that have the potential to significantly improve the lives of patients," said Dr. Rubio. "With the RT001 topical Phase 3 program underway and the Phase 3 program for RT002 injectable slated to begin later this year, I am excited to drive forward the clinical development efforts that can potentially lead to regulatory approvals and commercial launch within just a few years."
In connection with Dr. Rubio's employment agreement as Senior Vice President of Clinical Development of Revance, the Compensation Committee of Revance’s Board of Directors granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Dr. Rubio’s inducement awards consist of a stock option to purchase 110,000 shares of Revance common stock and 15,000 shares of restricted Revance common stock. Dr. Rubio's options will vest over a period of four years, with 25% vesting on March 14, 2017, and the balance vesting each month over the remaining three years. Dr. Rubio's restricted stock will vest over a period of four years starting April 15, 2016, with 25% vesting annually. These awards are subject to the terms and conditions of Revance's Amended and Restated 2014 Inducement Plan, as adopted by the Revance Board of Directors on December 11, 2015. These awards are effective on March 14, 2016, Dr. Rubio’s first day of employment with Revance, and the exercise price of the options will be today's closing price of Revance common stock on the NASDAQ Global Market.